Lincoln Pharmaceuticals has received approval to manufacture Hydroxychloroquine (HCQ) among other critical drugs to fight COVID 19. The company has received approval from Food & Drug Control Administration, Gujarat to manufacture varied dosages of Hydroxychloroquine Tablets and Hydroxychloroquine Sulfate Tablets among others at its plant in Khatraj in Ahmedabad.
After necessary approval from Directorate General of Foreign Trade (DGFT) company will be able to export these products. Food & Drug Control Administration, Gujarat approved manufacture of Hydroxychloroquine Sulfate Tablets USP in 200 MG, 300 MG and 400 MG dosages and Hydroxychloroquine Tablets IP in 200 MG, 300 MG and 400 MG dosages respectively from company’s Khatraj facility.
Lincoln Pharmaceuticals is engaged in the manufacture and marketing of affordable therapeutic products. The product range of the company includes Tablets, Capsules, Injectable, Syrups and Ointments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: